Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 11.150-11.450 for the period, compared to the consensus estimate of 11.090. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.8 billion.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Royal Bank Of Canada began coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $233.62 on Wednesday. The stock’s 50-day simple moving average is $209.54 and its two-hundred day simple moving average is $188.12. Charles River Laboratories International has a twelve month low of $144.26 and a twelve month high of $242.73. The firm has a market capitalization of $11.25 billion, a P/E ratio of -62.13, a P/E/G ratio of 2.57 and a beta of 1.38. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.74 by $0.28. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. During the same period in the previous year, the business earned $3.12 EPS. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts anticipate that Charles River Laboratories International will post 11.05 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of CRL. Invesco Ltd. grew its stake in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares during the period. Victory Capital Management Inc. boosted its position in shares of Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. increased its position in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after buying an additional 575,039 shares in the last quarter. Balyasny Asset Management L.P. raised its stake in Charles River Laboratories International by 722.5% during the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after buying an additional 381,432 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in Charles River Laboratories International by 120.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 644,726 shares of the medical research company’s stock worth $128,610,000 after acquiring an additional 352,549 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.